title: [Update in treatment of psoriatic arthritis].
abstract: Psoriatic arthritis is a chronic rheumatic disease making part of spondylarthropathies. It is the most frequent chronic inflammatory rheumatism after rheumatoid arthritis. Eventhough, it is usually a benign affection, it may be destructive leading to handicap. Several new medications have been introduced, including anti-tumor necrosis factor (TNF alpha blockers) and leflunomide for treatment of psoriatic arthritis. Many studies show the efficacy of these medications in this disease.
authors.affiliation: Service de rhumatologie, Hôpital Charles Nicolle, Tunis, Tunisie.
authors.forename: Leila Cheikhrouhou
authors.initials: LC
authors.lastname: Abdelmoula
authors.forename: Rim
authors.initials: R
authors.lastname: Ben M'Barek
authors.forename: Chiraz Ben Hadj
authors.initials: CB
authors.lastname: Yahia
authors.forename: Raoudha
authors.initials: R
authors.lastname: Tekaya
authors.forename: Nadia
authors.initials: N
authors.lastname: Testouri
authors.forename: Lilia
authors.initials: L
authors.lastname: Chaabouni
authors.forename: Rafik
authors.initials: R
authors.lastname: Zouari
mesh_terms: D000068879:Adalimumab; D000077944:Alefacept; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D003879:Dermatologic Agents / Q000627:therapeutic use; D006801:Humans; D007555:Isoxazoles / Q000627:therapeutic use; D000077339:Leflunomide; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D003879:Dermatologic Agents; D007555:Isoxazoles; D011993:Recombinant Fusion Proteins; D014409:Tumor Necrosis Factor-alpha; D000077944:Alefacept; D000068879:Adalimumab; D000077339:Leflunomide